Comorbidité physique chez les personnes âgées avec Trouble Bipolaire: Investigations pharmacoépidémiologiques


Soham REJ

Institut Lady Davis de recherches médicales de l'Hôpital général juif


Domaine :  neurosciences, santé mentale et toxicomanies

Programme chercheurs-boursiers-cliniciens  - Junior 1

Concours 2017-2018

Bipolar disorder is a highly disabling and costly condition affecting 1% of the population, with >50% of patients expected to be >age 60 by 2030. Medical problems are the main cause of 10-15 years reduced life expectancy in bipolar disorder and often prevent the use of effective therapies in late life. Two important unresolved issues in older age bipolar disorder are the risk of kidney disease, as well as neurological toxicity with the gold-standard bipolar disorder medication, lithium. In particular, the lithium level measured in the blood associated with a higher risk of kidney and neurological problems remains unknown in geriatric patients.

To better address these issues we are performing rigorous pharmacoepidemiological studies. These studies will use large national and international health databases, which contain millions of patients. Using that data, we will examine the relationship of potentially dangerous lithium levels with kidney and neurological problems in older adults using lithium.

One percent of the population uses lithium, while many more patients with bipolar disorder and depression, even potentially people with stroke and dementia, could potentially benefit from using lithium.  This exciting, cutting-edge program of research will help clinicians in Québec and internationally safely prescribe lithium for bipolar disorder and other conditions while minimizing medical problems, thereby improving physical and psychiatric health care in these patients.